Jill Caswell
Dr. Jill Caswell is the Biology Team Leader within Almac’s Biocatalysis group. After obtaining a degree in Biochemistry Jill worked in the industry producing recombinant proteins in a variety of host organisms before obtaining a PhD in 2011 through an industrial collaboration with Queen’s University Belfast.
Jill’s career has focussed on recombinant enzyme expression as well as molecular biology techniques that enable enzyme engineering. She joined Almac’s Biocatalysis group in 2012 with 10 years of industry-relevant experience to bring to the biology team, helping to grow the enzyme engineering capabilities.
Jason Hipp
Dan Nomura
Matthew Calabrese
John Castle
Wouter J de Jonge
Prof. dr. Wouter de Jonge, AGAF, received his doctoral training at University of Utrecht, and Columbia University New York, and received his PhD in 2001 (Medicine, University of Amsterdam and Maastricht). He took up postdoctoral positions at the AMC in Amsterdam (prof Guy Boeckxstaens-now in Leuven) and Oxford University (prof Siamon Gordon). He was appointed tenured assistant professor at Amsterdam UMC in 2009 and was appointed full professor in 2013. He currently chairs the gastro-intestinal research group (www.gut-research.com) at the Amsterdam UMC since 2013 and holds a part time professorship at the Dept of Surgery at the University of Bonn, Germany since 2018.
His work focusses on translational gastroenterology and the pathology of IBD. He is interested in gastrointestinal physiology and the function of neural networks within the gastrointestinal tract, in particular in relation to IBS and IBD. His work is funded via national Science Foundation grants (NWO-Vidi-STW), EU FP7, ECCO, and 2 Horizon2020 grants, Helmsley Foundation, Health Holland TKI topsector grants, and various public private partnership grants. He was co-founder of the Microbiome Center Amsterdam in 2016. He holds 5 patents. He served on the board of the scientific committees a.o. Dutch national trust for Gastro Intestinal and Lever Diseases, EU Marie Curie grants, AMC Valorisation Board, and serves as CEO on a spin off company AI-Biomics B.V., a company that develops predictive algorithms for disease biomarkers.
